Cardiac magnetic resonance changed the initial echocardiographic diagnostic suspicion of left ventricular hypertrophy in 42.7% of patients (p < 0.0001).
Observational (n=300)
Does CMR improve diagnostic accuracy and prognostic stratification in patients with echocardiographic and/or ECG signs of LVH?
CMR significantly improves the differential diagnosis of LVH compared to TTE and ECG, leading to diagnostic reclassification in nearly half of patients and impacting prognostic stratification.
p-value: p=< 0.0001
Background: Left ventricular hypertrophy (LVH) may be due to different causes, ranging from benign secondary forms to severe cardiomyopathies. Transthoracic Echocardiography (TTE) and ECG are the first-level examinations for LVH diagnosis. Cardiac magnetic resonance (CMR) accurately defines LVH type, extent and severity. Objectives: to evaluate the diagnostic and prognostic role of CMR in patients with TTE and/or ECG evidence of LVH. Methods: We performed CMR in 300 consecutive patients with echocardiographic and/or ECG signs of LVH. Results: Overall, 275 patients had TTE evidence of LVH, with initial suspicion of hypertrophic cardiomyopathy (HCM) in 132 (44%), cardiac amyloidosis in 41 (14%), hypertensive LVH in 48 (16%), aortic stenosis in 4 (1%), and undetermined LVH in 50 (16%). The initial echocardiographic diagnostic suspicion of LVH was confirmed in 172 patients (57.3%) and changed in 128 patients (42.7%, p < 0.0001): the diagnosis of HCM increased from 44% to 71% of patients; hypertensive and undetermined LVH decreased significantly (respectively to 4% and 5%). CMR allowed for a diagnosis in 41 out of 50 (82%) patients with undetermined LVH at TTE. CMR also identified HCM in 17 out of 25 patients with apparently normal echocardiography but with ECG criteria for LVH. Finally, the reclassification of the diagnosis by CMR was associated with a change in survival risk of patients: after CMR reclassification, no events occurred in patients with undetermined or hypertensive LVH. Conclusions: CMR changed echocardiographic suspicion in almost half of patients with LVH. In the subgroup of patients with abnormal ECG, CMR identified LVH (particularly HCM) in 80% of patients. This study highlights the indication of CMR to better characterize the type, extent and severity of LVH detected at echocardiography and suspected with ECG.
Aquaro et al. (Thu,) conducted a observational in Left ventricular hypertrophy (n=300). Cardiac magnetic resonance (CMR) vs. Transthoracic Echocardiography (TTE) and/or ECG was evaluated on Change in initial echocardiographic diagnostic suspicion of LVH (p=< 0.0001). Cardiac magnetic resonance changed the initial echocardiographic diagnostic suspicion of left ventricular hypertrophy in 42.7% of patients (p < 0.0001).